<table>
<thead>
<tr>
<th>AGENDA ITEM</th>
<th>PRESIDER/PRESENTER(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wednesday, October 28, 2020</strong></td>
<td></td>
</tr>
<tr>
<td><strong>10:00</strong> Welcome &amp; Introductions</td>
<td>Dr. José Romero (ACIP Chair)</td>
</tr>
<tr>
<td></td>
<td>Dr. Amanda Cohn (ACIP Executive Secretary, CDC)</td>
</tr>
<tr>
<td><strong>10:30</strong> Immunization Schedules</td>
<td>Dr. Hank Bernstein (ACIP, WG Co-Chair)</td>
</tr>
<tr>
<td></td>
<td>Dr. Kevin Ault (ACIP, WG Co-Chair)</td>
</tr>
<tr>
<td>Proposed changes to 2021 child/adolescent immunization schedule</td>
<td>Dr. Patricia Wodi (CDC/NCIRD)</td>
</tr>
<tr>
<td>Proposed changes to 2021 adult immunization schedule</td>
<td>Dr. Mark Freedman (CDC/NCIRD)</td>
</tr>
<tr>
<td><strong>11:30</strong> Seasonal Influenza Vaccines</td>
<td>Dr. Keipp Talbot (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>Dr. Gregg Sylvester (Seqirus)</td>
</tr>
<tr>
<td>Influenza Disease Burden and Vaccine Impact Estimates, 2019-20 Season</td>
<td>Dr. Carrie Reed (CDC/NCIRD)</td>
</tr>
<tr>
<td>End-of-Season Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness against Medically Attended Influenza from three U.S. Networks</td>
<td>Dr. Lisa Grohskopf (CDC/NCIRD)</td>
</tr>
<tr>
<td>Updates and WG Considerations</td>
<td>Dr. Lisa Grohskopf (CDC/NCIRD)</td>
</tr>
<tr>
<td><strong>12:30</strong> Lunch</td>
<td></td>
</tr>
<tr>
<td><strong>1:15</strong> Orthopoxvirus Vaccine</td>
<td>Dr. Beth Bell (ACIP, WG Chair)</td>
</tr>
<tr>
<td></td>
<td>Dr. Brett Petersen (CDC/NCEZID)</td>
</tr>
<tr>
<td>Varicella virus plaque reduction neutralization assay for the</td>
<td>Dr. Heinz Weidenthaler (Bavarian Nordic)</td>
</tr>
<tr>
<td>Vaccinating against monkeypox in the Democratic Republic of the Congo with JYNNEOS*</td>
<td></td>
</tr>
<tr>
<td>Next Steps</td>
<td>Dr. Agam Rao (CDC/NCEZID)</td>
</tr>
<tr>
<td><strong>2:45</strong> Break</td>
<td></td>
</tr>
<tr>
<td><strong>2:55</strong> Dengue Vaccines</td>
<td>Dr. Robert Atmar (ACIP, WG Chair)</td>
</tr>
<tr>
<td><strong>3:05</strong> Pneumococcal Vaccines</td>
<td>Dr. Katherine Poehling (ACIP, WG Chair)</td>
</tr>
<tr>
<td>Work group introduction</td>
<td>Dr. Miwako Kobayashi (CDC/NCIRD)</td>
</tr>
<tr>
<td><strong>3:15</strong> Cholera Vaccines</td>
<td>Dr. Pablo Sanchez (ACIP, WG Chair)</td>
</tr>
<tr>
<td>Work group introduction</td>
<td></td>
</tr>
<tr>
<td><strong>3:25</strong> Break</td>
<td></td>
</tr>
<tr>
<td><strong>3:30</strong> Public Comment</td>
<td></td>
</tr>
<tr>
<td><strong>4:15</strong> Break</td>
<td></td>
</tr>
<tr>
<td><strong>4:20</strong> Vote - Immunization Schedules</td>
<td>Dr. Mark Freedman (CDC/NCIRD)</td>
</tr>
<tr>
<td><strong>4:30</strong> Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, October 29, 2020

10:00 Unfinished Business and Agency Updates  
CDC, CMS, FDA, HRSA, IHS, NIH, OIDP

10:15 Zoster Vaccine  
Introduction  
Dr. Grace Lee (ACIP, WG Chair)  
Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix) in the Vaccine Adverse Event Reporting System (VAERS)  
Dr. John Su (CDC/NCEZID)  
Vaccine Safety Datalink (VSD) update on post-licensure safety monitoring of RZV  
Dr. Jennifer Nelson (Kaiser Permanente)  
Risk of Guillain-Barré syndrome following herpes zoster  
Dr. Tara Anderson (CDC/NCIRD)  
Summary and planned risk-benefit analysis regarding use of RZV in immunocompetent adults  
Dr. Tara Anderson (CDC/NCIRD)  
Planned risk-benefit analysis regarding use of RZV in immunocompetent adults  
Dr. Tara Anderson (CDC/NCIRD)  

11:45 Lunch

12:20 Tick-borne Encephalitis Vaccine  
Introduction  
Dr. Katherine Poehling (ACIP, WG Chair)  
Overview of tick-borne encephalitis (TBE) and TBE vaccine  
Dr. Susan Hills (CDC/NCEZID)  
Immunogenicity and safety of Pfizer’s TBE vaccine  
Dr. Dr Heinz-Joseph Schmitt (Pfizer)  
Next steps for TBE vaccine work group  
Dr. Susan Hills (CDC/NCEZID)

2:00 Break

2:15 Rabies Vaccine  
Introduction  
Dr. Sharon Frey (ACIP, WG Chair)  
Minimum acceptable rabies antibody titer and implications on ACIP recommendations  
Dr. Susan Moore (Kansas State University)  
Pertinent fundamentals of rabies immunology  
Dr. Deborah Briggs (Kansas State University)  

3:30 Break

3:30 Pre-exposure prophylaxis schedule: Grading of recommendations assessment, development, and evaluation (GRADE)  
Dr. Agam Rao (CDC/NCEZID)  
Evidence to recommendation framework (EtR)  
Dr. Agam Rao (CDC/NCEZID)  
Summary and next steps  
Dr. Agam Rao (CDC/NCEZID)

4:50 Adjourn
Friday, October 30, 2020

10:00 Coronavirus Disease 2019 (COVID-19) Vaccines

Introduction
Update from Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting
NVX-CoV2373 Vaccine Candidate
Janssen’s SARS-CoV-2 Vaccine Program

Dr. Beth Bell (ACIP, WG Chair)
Dr. Doron Fink (FDA)
Dr. Filip Dubovsky (Novavax)
Dr. Jerry Sadoff (Janssen)

11:45 Break

12:00 Update on vaccine implementation planning
Vaccinate with Confidence

Dr. Janell Routh (CDC/NCIRD)
Dr. Amanda Cohn (CDC/NCIRD)

12:30 Lunch

1:15 FDA safety surveillance systems
Post-authorization safety monitoring plans
Modeling strategies for the initial allocation of COVID-19 vaccines
Discussion

Dr. Steven Anderson (FDA)
Dr. Tom Shimabukuro (CDC/NCEZID)
Dr. Matthew Biggerstaff (CDC/NCIRD)

2:30 Break

2:45 Updates to immunity and epidemiology to inform COVID-19
Ethical principles for early vaccine allocation
Work Group interpretation of data
Policy questions, Evidence to Recommendation Framework, and Discussion

Dr. Megan Wallace (CDC/NCIRD)
Dr. Mary Chamberland (CDC/NCIRD)
Dr. Sara Oliver (CDC/NCIRD)
Dr. Kathleen Dooling (CDC/NCIRD)

4:45 Adjourn

Acronyms

CDC Centers for Disease Control and Prevention
CMS Centers for Medicare and Medicaid Services
COVID-19 Coronavirus Disease 2019
EIR Evidence to Recommendations Framework
FDA Food and Drug Administration
GRADE Grading of Recommendations Assessment, Development and Evaluation
HRSA Health Resources and Services Administration
IHS Indian Health Service
NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID National Institute of Allergy and Infectious Diseases
OIDP Office of Infectious Disease and HIV/AIDS Policy
RZV Recombinant Zoster Vaccine
SAGE Strategic Advisory Group of Experts
SARS-CoV-2 Severe Acute Respiratory Syndrome coronavirus 2
WG Work Group
WHO World Health Organization
VAERS Vaccine Adverse Event Reporting System
VE Vaccine Effectiveness